Central serous chorioretinopathy (CSCR) is an ocular condition in which fluid build-up accumulates underneath the retina, resulting in detachment and vision loss. Some patients show irreversible functional and anatomical changes in the retina. |
Photobiomodulation (PBM) treatment uses light wavelengths to improve cellular function and has recently shown positive effects in several ocular conditions including those with edema. |
A 39-year-old female patient with CSCR showed significant improvements in vision (best-corrected visual acuity) and resolution of fluid build-up immediately following multiwavelength PBM therapy with Valeda. |
PBM is a non-invasive treatment option that may provide benefit in CSCR to resolve inflammation, fluid build-up, and vision decline. Further research is warranted to confirm if PBM is effective as a treatment for CSCR. |
Introduction
Case Presentation
Follow-Up and Outcomes
Visit | BCVA (OS eye) | Central retinal thickness (CRT) |
---|---|---|
Baseline | 65 letters | 535 μm |
Follow-up observational visit | 55 letters | 544 μm |
Multiwavelength PBM Tx initiated | ||
Week 1 PBM Visit (3 PBM Tx) | 65 letters | 367 μm |
Week 2 PBM Visit (6 PBM Tx) | 70 letters | 284 μm |
Week 3 PBM Visit (9 PBM Tx) | 80 letters | 231 μm |
Follow-up treatment visit (repeated PBM Tx series initiated at ~ 6-months) | 80 letters | 224 μm |
Follow-up observational Visit (~ 1 year) | 80 letters | 219 μm |